| Document |
Document Title |
|
WO/2018/233326A1 |
A hydrogen sulfide donor in an organic salt form and a preparation method therefor. The hydrogen sulfide donor is a salt structure formed by organic compounds with an alkaline structure and hydrogen sulfide. The hydrogen sulfide donor ha...
|
|
WO/2018/226368A1 |
A method for removing carbon dioxide from a gaseous source, the method comprising: (i) contacting said gaseous source with an aqueous solution of a carbon dioxide sorbent that reacts with carbon dioxide to form an aqueous-soluble carbona...
|
|
WO/2018/216926A1 |
Provided is a composition containing an alkyl lactate, an anti-hydrolysis agent, and water, wherein the anti-hydrolysis agent is a basic amino acid.
|
|
WO/2018/210633A1 |
The present invention relates to a method for the production of phenylguanidines or the salts thereof by reacting an aniline that has electronegative substituents with a cyanamide-containing mixture.
|
|
WO/2018/208647A1 |
Provided are embodiments of creatine and creatine ethyl ester (CEE) salts where the anion is an artificial (non-saccharide) taste-modifier. These compounds represent stable white non-hygroscopic solids or semisolids that can readily diss...
|
|
WO/2018/172168A1 |
The present invention relates to a guanidine of the formula (I) and to the use thereof as catalyst for the crosslinking of a functional compound, especially a polymer having silane groups. The guanidine of the formula (I) described is pr...
|
|
WO/2018/170306A1 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
WO/2018/159650A1 |
The purpose of the present invention is to provide a compound which has a guanidine skeleton and inhibits the protease activity of MALT1 to exhibit a therapeutic effect or prophylactic effect on autoimmune diseases such as psoriasis. The...
|
|
WO/2018/135977A1 |
The invention relates to the field of pharmaceutical chemistry, namely to new biologically active substances and their use and to a method of production. In particular, the invention relates to a derivative of creatine - phenylcreatine, ...
|
|
WO/2018/132827A1 |
Disclosed is nucleic acid preserving compositions and methods of manufacturing and using the same. Compositions include a carrier, a chaotropic agent, a buffering agent, a chelating agent, a surfactant, an alcohol, an acid, and a mucolyt...
|
|
WO/2018/106938A1 |
The present disclosure is directed to polymeric coatings. The coatings can include a substrate-coordinating functionality as well as additional functionality for interacting with the surrounding environment. For example, the coatings can...
|
|
WO/2018/106907A1 |
The present invention provides novel fused bicyclic alkylene linked imidodicarbonimidic diamides. In particular, described herein are N-[2-(indol-3- yl)alkylene]-linked imidodicarbonimidic diamides and N-[2-(pyrrolopyridin-3- yl)alkylene...
|
|
WO/2018/097172A1 |
The present invention provides: compounds represented by formula (IV) (in the formula, Ar represents a substituted or unsubstituted phenylene group; X and Z each independently represent a substituted or unsubstituted alkylene group, etc....
|
|
WO/2018/096504A1 |
Compounds of Formula (I), including stereoisomers and salts thereof, and compositions, methods of treatment and prevention, and methods of preparing, the same: Formula (I) wherein X is O or a direct bond; wherein when X is O, R1 and R2 a...
|
|
WO/2018/097126A1 |
Compounds represented by formula (I) or salts thereof. A fungicide or plant disease control agent containing as an active ingredient at least one selected from the group consisting of said compounds and salts thereof. In formula (I), Ar ...
|
|
WO/2018/087753A1 |
The present invention provides cationic lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their int...
|
|
WO/2018/081869A1 |
The present application relates to compounds of Formula (I) and salts thereof. The compounds of Formula (I) have antibacterial and anti-biofilm activities. The present application also relates to compositions comprising the compounds of ...
|
|
WO/2018/060373A1 |
The present invention relates to drugs derived from elafibranor. It relates more specifically to a composition comprising at least one active ingredient, characterised in that at least one active ingredient comprises an elafibranor metfo...
|
|
WO/2018/060962A2 |
The present invention relates to metformin amino acid compounds (SLNs), pharmaceutical compositions thereof, and methods of using them for the treatment of hyperglycemia, diabetes, and Type 2 diabetes. The compounds can be synthesized us...
|
|
WO/2018/060959A1 |
The present disclosure relates to metformin glycinate and methods of using metformin glycinate for the treatment of diseases including diabetes mellitus, obesity, dyslipidemia, diseases associated with IL-10 up-regulation, and diseases o...
|
|
WO/2018/053643A1 |
Described herein are compositions and methods for modulating cellular senescence of a cell or induction of the senescence-associated secretory phenotype (SASP) in a cell. The methods generally comprise modulating the level or activity of...
|
|
WO/2018/035408A1 |
Methods of treating developmental disorders such as Angelman syndrome, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome (FXTAS), Autistic Spectrum Disorder, Autism, Asperger's syndrome, pervasive developmental disorder, Ch...
|
|
WO/2018/029618A1 |
An antibacterial compound of formula I, wherein X is selected from fluoro or bromo, effective against Gram negative and Gram positive bacteria, and in particular against non-fermenting multiresistant bacteria affecting patients suffering...
|
|
WO/2018/014111A1 |
There is provided methods, compositions and treatment regimens for treating cancer, or for inhibiting metastasis/recurrence of cancer in a patient using 1) a primary cancer treatment such as chemotherapy, and 2) within 12 to 120 hours po...
|
|
WO/2017/205828A1 |
This invention relates to using a guanidinium-based ionic liquid as an absorbent material in an absorption chiller. The invention provides an absorption chiller comprising a mixture of a refrigerant and an absorbent, and the absorbent is...
|
|
WO/2017/205807A1 |
This invention relates to using a eutectic mixture of two ionic liquids, as an absorbent material in an absorption chiller. The invention provides an absorption chiller comprising a mixture of a refrigerant and an absorbent, and the abso...
|
|
WO/2017/197510A1 |
A biocompatible composite material for controlled release is disclosed, comprising a biocompatible metal oxide structure with a loaded network of pores. The pore network of the biocompatible composite material is filled with a uniformly ...
|
|
WO/2017/195086A1 |
The present invention provides novel metformin salts, method of preparing, and pharmaceutical compositions containing the same. The metformin sesquihydrochloride and metformin dihydrochloride according to the present invention has improv...
|
|
WO/2017/176246A1 |
Compositions and methods for cleansing the eyelid and treating an ocular condition are disclosed herein. A method for treating an ocular condition involves cleansing an eyelid with a first ophthalmic composition, wherein the first ophtha...
|
|
WO/2017/164813A1 |
D The present invention relates to ion pair catalysts (I) comprising the cationic bisguanidinium ligand (A) and diperoxomolybdate anion (B). The present invention also relates to ion pair catalysts (III) comprising the cationic bisguanid...
|
|
WO/2017/158379A1 |
The present invention provides a crystalline salt of chlorhexidine chloride having a spherical morphology under Scanning Electron Microscopy (SEM) comprising a chloride anion and a cation selected from the group consisting of calcium, so...
|
|
WO/2017/118582A1 |
The invention relates to an aqueous plating bath composition for electroless deposition of nickel or a nickel alloy, the composition comprising: (i) a source of nickel ions, wherein the aqueous plating bath composition further comprises ...
|
|
WO/2017/119562A1 |
The present invention relates to an antithrombotic, antiplatelet and anticoagulant pharmaceutical composition containing, as an active ingredient, a compound isolated from Scolopendra subspinipes. More specifically, the compound of the p...
|
|
WO/2017/114224A1 |
The present invention discloses a creatine mother liquor separation and purification processing system, wherein the system includes a mother liquor tank for containing the mother liquor following creatine synthesis, the mother liquor tan...
|
|
WO/2017/114226A1 |
Disclosed in the present invention is a method for separating and purifying a creatine mother liquor: by means of a liquor delivery tube, pumping a mother liquor after creatine synthesis to be separated in an electrodialyzer, wherein the...
|
|
WO/2017/106312A1 |
Embodiments described herein provide methods of treating various diseases or disorders using Sigma1 modulating compounds alone or in combination with other therapeutic agents.
|
|
WO/2017/078467A1 |
The present invention relates to a composition for skin permeation to deliver a protein into skin, wherein the composition comprises an ionic conjugate in which a cationic compound and a protein are ionically bound. As the ionic conjugat...
|
|
WO/2017/070482A2 |
PPSMA binding scaffolds with radioiodinated, radiobrominated and radioastatinated labeled prosthetic groups are disclosed. Pharmaceutical compositions and methods of treating PSMA expressing cells or tumors also are disclosed.
|
|
WO/2017/065495A2 |
The present invention relates to a compound for inhibiting the secretion of thymic stromal lymphopoietin (TSLP) from mast cells, and a use thereof. It has been confirmed that the compound of the present invention significantly inhibits t...
|
|
WO/2017/063155A1 |
The present invention provides compounds of formula I. The present invention also provides a preparation method for the compounds and a medicine composition comprising the compounds. The medicine composition can be used for treating a bo...
|
|
WO/2017/051761A1 |
The prodrug or a salt thereof according to the present invention is represented by the formula: D-X-L. (In the formula, D represents a useful compound and becomes D-X-H. X represents NR1, O, S, or Se. R1 represents a hydrogen atom, a sub...
|
|
WO/2017/049245A2 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
WO/2017/043842A1 |
The present invention relates to a method for preparing D-arginine and, more particularly, to a method for preparing D-arginine by photosplitting DL-arginine using D-3-bromocamphor-8-sulfonic acid or a salt thereof as a photosplitting ag...
|
|
WO/2017/042099A1 |
The present invention relates to compounds of formula I or pharmaceutically acceptable salt, solvate or hydrate thereof wherein ASC is -N(R8)ASC-1; ASC-1 is C 2-C 5alkylene-N(R9a)R9b or C(=O)-C 1-C 4alkylene-N(R9a)R9b, wherein in alkylen...
|
|
WO/2017/042126A1 |
The invention relates to a method for producing biguanide salts of formula (III) and s-triazines of the formula (V). R1 and R2 respectively represent hydrogen, halogen and alkyl and R3 and R4 each represent hydrogen, alkyl, cycloalkyl an...
|
|
WO/2017/035668A1 |
An applicator can have an ampoule body for holding a medial liquid; a tab extending away from the ampoule body and being twistable or deflectable with respect to a longitudinal axis of the ampoule body; and a frangible region in between ...
|
|
WO/2017/027971A1 |
The present application is directed to transdermal formulations for the delivery of berberine compounds to a subject for the treatment of berberine-responsive diseases. In particular, the transdermal formulation comprises: (a) an aqueous...
|
|
WO/2017/025560A1 |
The present invention relates to a process for the preparation of the compound N-(3,5-dimethylphenyl)-N'-(2-trifluoromethylphenyl) guanidine of formula (I) which comprises reacting a salt of a compound of formula (II) or a mixture of the...
|
|
WO/2017/027582A1 |
Compounds, pharmaceutical compositions, methods and kits are described for treating or preventing neurodegenerative diseases such as Alzheimer's disease.
|
|
WO/2017/023833A1 |
The present invention is directed to combination pharmacological treatments that induce a prolonged, modest decrease in core body temperature, to the range of ~95°F to ~98.5°F (~35°C to ~36.7°C) to mitigate and delay the early onset ...
|
